Areas of Interest
-
Autoimmune
Asahi Kasei Pharma (AKP) discovered, developed, and markets the immunosuppressant Bredinin™ (mizoribine) for rheumatoid arthritis (RA). Under license, AKP markets Kevzara® (sarilumab) for the treatment for RA and Plaquenil® for the treatment of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE), and is developing AK1910/SBI-3150 for SLE. AKP is building strong portfolio in this field through research collaboration and in-licensing activities. -
Musculoskeletal (including medical devices)
AKP discovered, developed, and markets the osteoporosis therapeutic agent Teribone™ (teriparatide acetate) and the synthetic calcitonin derivative Elcitonin™ (elcatonin) for osteoporosis pain. Under license, AKP developed and markets the bisphosphonate Reclast™ (zoledronic acid) for the treatment of osteoporosis. AKP obtained exclusive option for AGN1 LOEP Hip Kit, a medical material under development by AgNovos. AKP is seeking pharmaceuticals and medical devices especially medical materials in the musculoskeletal field to expand its portfolio. -
Pain management (including medical devices)
AKP discovered, developed, and markets the synthetic calcitonin derivative Elcitonin™ (elcatonin) for osteoporosis pain. Under license, AKP is currently conducting clinical studies of AK1830/ARRY-954 for osteoarthritic pain and low back pain. AKP conducted several Phase 1 studies for AK1780, which had been created through collaboration with RaQualia. AK1780 is currently referred to as LY3857210 and under Phase 2 trial for chronic pain conditions by Eli Lilly. AKP is seeking pharmaceuticals and medical devices especially Digital Therapeutics (DTx) opportunities to build strong portfolio in this field. -
Severe infectious diseases
Under license, AKP developed and markets Cresemba™ (isavuconazonium sulfate) for fungal infections (aspergillosis, mucormycosis, and cryptococcosis). AKP is trying to expand its portfolio in the severe infectious diseases field through in-licensing activities. -
Specialty (e.g. ICU and refractory hematologic or gastrointestinal disorders)
AKP discovered, developed, and markets the biologic Recomodulin™ (thrombomodulin alfa) for disseminated intravascular coagulation (DIC). Under license, AKP is collaborating to develop apraglutide, a next-generation, long-acting GLP-2 analog peptide for the treatment of short bowel syndrome with intestinal failure (SBS-IF). Under license, AKP markets Empaveli® (pegcetacoplan), a complement C3 protein inhibitor for paroxysmal nocturnal hemoglobinuria, and for Doptelet® (avatrombopag maleate), an agent for improving thrombocytopenia in patients with chronic liver disease who are scheduled to undergo an invasive procedure. AKP is seeking opportunities in specialty field, especially diseases treated by ICU physicians, or refractory hematologic or gastrointestinal disorders, to further expand its portfolio.
